Bioventus Agrees to Nationwide Contract with UnitedHealthcare® Commercial Plans Members Have Access to DUROLANE® and GELSYN-3®for Knee Osteoarthritis [...]

Bioventus Launches DUROLANE® SJ (1mL) in Australia and New Zealand; Receives Expanded Indications for DUROLANE (3mL) HOOFDDORP, THE NETHERLANDS – Augu [...]

Bioventus to Co-Develop Next Generation Placental Tissue Product for Knee Osteoarthritis with MTF Biologics DURHAM– June 6, 2019 – Bioventus, a global [...]

Bioventus Launches OSTEOAMP SELECT Fibers DURHAM, NC – March 27, 2019 – Bioventus, a global leader in orthobiologic solutions, is launching OSTEOAMP S [...]

Bioventus Launches DUROLANE® in Malaysia and Selects Athrotech as Exclusive Distribution Partner HOOFDDORP, THE NETHERLANDS – January 29, 2019 – Biove [...]

Bioventus Launches OSTEOMATRIX+® Biphasic Bone Graft DURHAM, NC – January 15, 2019 – Bioventus, a global leader in orthobiologic solutions, is launchi [...]

Susan M. Stalnecker Named to Bioventus Board of Managers DURHAM, NC – October 25, 2018 – Bioventus, a global leader in orthobiologic solutions, today [...]

Bioventus Receives ANVISA Approval to Market DUROLANE® in Brazil and Selects Pfizer as Exclusive Distribution Partner HOOFDDORP, THE NETHERLANDS – Oct [...]

Bioventus Enters Into Definitive Agreement to Divest BMP Development Program to Viscogliosi Brothers, LLC DURHAM, NC – July 23, 2018 – Bioventus, a gl [...]

Bioventus Launches DUROLANE® in the US DURHAM, NC - March 5, 2018 – Bioventus, a global leader in orthobiologic solutions, today launched DUROLANE, it [...]